The glycosylated extracellular domain of MUC1 protects against SARS-CoV-2 infection at the respiratory surface

Maitrayee Chatterjee; Liane Z.X Huang; Chunyan Wang; Anna Z Mykytyn; Bart Westendorp; Richard W Wubbolts; Berend Jan Bosch; Bart Haagmans; Jos P.M van Putten; Karin Strijbis.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-466408

Documentos relacionados

  1. Glycosylated extracellular mucin domains protect against SARS-CoV-2 infection at the respiratory surface.
  2. The role of mucin <i>O</i>-glycans in microbiota dysbiosis, intestinal homeostasis, and host-pathogen interactions.
  3. Mucin O-glycans are natural inhibitors of Candida albicans pathogenicity.
  4. Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor-binding affinity.
  5. Mirror Image Mucins and Thio Mucins with Tunable Biodegradation.
  6. Comprehensive clinicopathological characteristics and mucin core protein expression profiles of bronchiolar adenoma.
  7. Structure and Function of Surface Polysaccharides of Staphylococcus aureus.
  8. The Glycan-Binding Trait of the Sarbecovirus Spike N-Terminal Domain Reveals an Evolutionary Footprint.
  9. Structural O-Glycoform Heterogeneity of the SARS-CoV-2 Spike Protein Receptor-Binding Domain Revealed by Top-Down Mass Spectrometry.
  10. Elucidation of <i>N</i>-/<i>O</i>-glycosylation and site-specific mapping of sialic acid linkage isomers of SARS-CoV-2 human receptor angiotensin-converting enzyme 2.